Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 14/20 | 1.00 |
| ▸ | JAK2 | O60674 | 11/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Londamocitinib SCHEMBL30018267 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| Londamocitinib SCHEMBL30018109 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| Londamocitinib SCHEMBL20399350 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| Londamocitinib SCHEMBL20399407 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL30092442 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL30092441 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL30092439 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL20399594 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL20399595 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL20399598 | 0.97 | JAK1 (1.00) | JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | claimed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | claimed |
| CN-112424187-B | Xinafoate salts of JAK inhibiting compounds | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-11897869-B2 | JAK1 selective inhibitors | ASTAZENECA AB (SE) | 2024-02-13 | — | — | US | claimed |
| EP-4219470-A1 | JAK1 SELECTIVE INHIBITORS | Astrazeneca AB (SE) | 2023-08-02 | — | — | EP | claimed |
| EP-3571192-B1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2022-11-30 | — | — | EP | claimed |
| US-11149029-B2 | Salts of IJAK inhibitors and methods of using the same | ASTRAZENECA AB (SE) | 2021-10-19 | — | — | US | claimed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | claimed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | claimed |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| CN-112424187-B | Xinafoate salts of JAK inhibiting compounds | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20200062737-A1 | NOVEL SALTS OF IJAK INHIBITORS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2020-02-27 | — | — | US | disclosed |
| US-20200062737-A1 | NOVEL SALTS OF IJAK INHIBITORS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2020-02-27 | — | — | US | disclosed |
| WO-2020016302-A1 | A XINAFOATE SALT OF A JAK INHIBITING COMPOUND | ASTRAZENECA AB (SE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016302-A1 | A XINAFOATE SALT OF A JAK INHIBITING COMPOUND | ASTRAZENECA AB (SE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 14/4885 |
| US-11897869-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 14/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 247/4885 |
| US-11149029-B2 | Salts of IJAK inhibitors and methods of using the same | KHK, NEK5, HYPK | JAK1 429/4885JAK2 574/4885TYK2 206/4885 |
| US-20200062737-A1 | NOVEL SALTS OF IJAK INHIBITORS AND METHODS OF USING THE SAME | NEK5, NEK7, NEK9 | JAK1 321/4885JAK2 539/4885TYK2 122/4885 |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 14/4885 |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.